Zurück zur Übersicht
| Immunotherapy. 2022 Apr 25. doi: 10.2217/imt-2021-0207 |
| Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis. |
| Yanagisawa T1, Mori K2, Katayama S3, Mostafaei H4, Quhal F5, Laukhtina E6, Rajwa P7, Motlagh RS8, Aydh A9, König F10, Grossmann NC11, Pradere B12, Miki J13, Schmidinger M14, Egawa S15, Shariat SF16 |
 Author information
|
|
Abstract We aimed to assess the prognostic value of pretreatment hematological biomarkers in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICIs). PubMed, Web of Science and Scopus databases were searched for articles according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Fifteen studies comprising 1530 patients were eligible for meta-analysis. High levels of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-reactive protein and lactate dehydrogenase were significantly associated with worse progression-free survival. High NLR and PLR were significantly associated with worse overall survival. High pretreatment NLR and PLR appear to be hematological prognostic factors of progression and overall mortality in mRCC patients treated with ICIs. These findings might help in the design of correlative biomarker studies to guide the clinical decision-making in the immune checkpoint inhibitor era. |
|
KEYWORDS: C-reactive protein, PD-1, immune checkpoint inhibitor, lactate dehydrogenase, meta-analysis, metastatic renal cell carcinoma, neutrophil-to-lymphocyte ratio, nivolumab, platelet-to-lymphocyte ratio, prognostic factor |
|
Publikations ID: 35465726 Quelle: öffnen |
Author information
Schnellinfo
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
